An observational study in Germ Cell Tumor, Yolk Sac Tumor and Embryonal Carcinoma, sponsored by Ankara City Hospital Bilkent. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Ankara City Hospital Bilkent · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Extracranial malignant germ cell tumors (GCTs) account for about 3% of childhood cancers. The current international risk classification (Malignant Germ Cell International Consortium, MaGIC) is based on age, primary tumor site and stage, and does not include how tumor markers respond during treatment. Serum alpha-fetoprotein (AFP) is measured routinely in nearly all of these children.
This national, multicenter, retrospective cohort study will evaluate whether the rate of AFP decline during first-line treatment predicts event-free survival independently of MaGIC risk factors. The medical records of children younger than 18 years diagnosed with an extracranial malignant non-germinomatous GCT between January 2014 and December 2025 and treated at participating pediatric oncology centers in Turkey will be reviewed. No new tests, samples, visits or interventions are required.
Secondary aims are to evaluate the prognostic value of AFP at diagnosis and of beta-human chorionic gonadotropin (beta-hCG) decline kinetics, to describe postoperative AFP kinetics in patients managed with surgery alone, to describe how relapses are detected, to quantify long-term treatment-related toxicity according to treatment intensity, and to explore a subgroup of patients who might be candidates for treatment reduction in future prospective studies.
Design: National, multicenter, retrospective cohort study coordinated by the Pediatric Hematology and Oncology Clinic of Ankara Bilkent City Hospital, conducted with the Turkish Pediatric Oncology Group (TPOG). Consecutive eligible patients diagnosed on or after 01 January 2014 whose first-line treatment ended on or before 31 December 2025 will be included, giving every patient at least 12 months of potential follow-up after the end of first-line treatment. The data lock date for follow-up is 31 December 2026. The study will be reported according to the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) and REMARK (Reporting Recommendations for Tumor Marker Prognostic Studies) guidelines. The protocol, including pre-specified primary and secondary analyses, is registered before data collection begins.
Data collection: Local investigators at each participating center will abstract data from medical records and hospital information systems into a standardized, pseudonymized electronic case report form hosted on the coordinating center's institutional server in Turkey. No direct identifiers will be transferred to the coordinating center. Centers will enter only raw tumor marker values and dates; all derived variables (marker kinetics, age-adjusted AFP, MaGIC risk group, estimated glomerular filtration rate [eGFR]) will be calculated centrally with a single pre-specified analysis code. Data collected include demographics and predisposing conditions, tumor characteristics (site, World Health Organization [WHO] histology, stage by Children's Oncology Group [COG] or International Federation of Gynecology and Obstetrics [FIGO] criteria, International Germ Cell Cancer Collaborative Group [IGCCCG] risk group where applicable), surgery, chemotherapy and radiotherapy details including cumulative drug doses, all serial AFP, beta-human chorionic gonadotropin (beta-hCG) and lactate dehydrogenase (LDH) values with dates, liver function tests around AFP measurements, outcomes, and long-term toxicity.
AFP definitions: AFP values measured before 12 months of age will be interpreted using age-specific reference ranges for term and preterm infants, with continuous reference intervals derived from generalized additive models for location, scale and shape (GAMLSS) in sensitivity analysis. AFP at diagnosis will be expressed as log10 AFP and as multiples of the age-specific median (MoM).
Tumor marker kinetics: Serum AFP is measured on day 1 of each chemotherapy cycle before drug administration (each cycle is 21 days; generally 4 cycles, up to 6 cycles in some patients), at the end of first-line treatment and during follow-up, so that the AFP response is assessed after every cycle. (1) AFP half-life (primary kinetic exposure), calculated from the cycle 1 day 1 value with values in the first 7 days after chemotherapy start excluded to avoid surge; satisfactory decline is defined, consistent with the MaGIC definition, as normalization within the first two post-baseline measurements or a half-life of 7 days or less; (2) early decline ratio (cycle 2 day 1 / baseline); (3) observed-versus-expected decline area; (4) time to normalization; (5) patient-specific log-AFP slope from a linear mixed-effects model; (6) beta-hCG half-life (satisfactory if 3 days or less). Postoperative AFP kinetics will be calculated separately for patients managed with surgery alone.
Statistical analysis: Survival will be estimated by Kaplan-Meier and compared by log-rank test; cumulative incidence of relapse will be estimated with the Aalen-Johansen estimator (Gray test, Fine-Gray models in sensitivity analysis). To avoid immortal time bias, AFP kinetic analyses will use a landmark at the start of chemotherapy cycle 3 (each cycle is 21 days; approximately day 43 after the start of chemotherapy). Multivariable Cox models will be adjusted for MaGIC risk group, with a shared frailty term for center. Pre-specified interactions of AFP kinetics with age (\<11 vs >=11 years) and MaGIC risk group will be tested. A joint model of longitudinal log-AFP and time to event will be fitted as a complementary analysis. Incremental prognostic value will be assessed by Harrell's concordance index (C-index), time-dependent area under the receiver operating characteristic curve (AUC) at 3 years, calibration with bootstrap optimism correction, internal-external cross-validation by center when feasible, and decision curve analysis. Missing covariates will be handled by multiple imputation by chained equations (MICE); kinetic parameters will not be imputed.
Sample size: Assuming unsatisfactory AFP decline in about 12% of patients and a hazard ratio of 3.0 for event-free survival, 62 events are required for 80% power at two-sided alpha 0.05 (Schoenfeld method). With an event rate of about 15%, the target AFP kinetic cohort is approximately 320-420 patients. If fewer events occur, Firth's penalized likelihood will be used and results will be presented as exploratory.
Exploratory treatment-reduction analysis: Before any outcome data are analyzed, patients with MaGIC low- or standard-risk disease, satisfactory AFP decline and cisplatin-based chemotherapy will be defined as a candidate treatment-reduction subgroup. Relapse rates and long-term toxicity as a function of number of cycles and cumulative platinum dose will be described. This analysis is hypothesis-generating only.
166 studies on the registry are indexed under Neoplasms, Germ Cell and Embryonal; 48 are open to participants now.
This study's planned enrollment of 400 is above the median of 279 across 33 observational studies indexed under Neoplasms, Germ Cell and Embryonal.
Browse Neoplasms, Germ Cell and Embryonal studies →Ankara City Hospital Bilkent is the lead sponsor of 450 studies on the registry; 110 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Children and adolescents younger than 18 years diagnosed with an extracranial malignant non-germinomatous germ cell tumor between January 2014 and December 2025 and treated at participating pediatric hematology-oncology centers in Turkey (coordinating center: Ankara Bilkent City Hospital, including records of the former Ankara Children's Health and Diseases Hematology Oncology Training and Research Hospital). All consecutive eligible patients at each center will be included.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients younger than 18 years at diagnosis with a histologically confirmed extracranial malignant non-germinomatous germ cell tumor (yolk sac tumor, embryonal carcinoma, choriocarcinoma, polyembryoma, mixed malignant germ cell tumor, or immature teratoma with a malignant component), diagnosed on or after 01 January 2014 and completing first-line treatment (surgery alone or surgery plus chemotherapy) on or before 31 December 2025 at a participating center. Exposure of interest: serum AFP decline kinetics during first-line treatment (satisfactory vs unsatisfactory decline), as recorded during routine care. No study intervention is given.
Event-free survival according to alpha-fetoprotein (AFP) decline kinetics
Association between unsatisfactory AFP decline during first-line treatment (AFP half-life \>7 days, or no normalization within the first two post-baseline measurements, consistent with the Malignant Germ Cell International Consortium \[MaGIC\] definition) and event-free survival, adjusted for MaGIC risk group (age, primary site, stage), estimated by hazard ratio from a multivariable Cox model with a landmark at the start of chemotherapy cycle 3 (each cycle is 21 days). AFP is measured on day 1 of each chemotherapy cycle before drug administration (generally 4 cycles, up to 6 cycles in some patients). Events: relapse, progression, second malignant neoplasm or death from any cause, whichever occurs first.
Time frame: From the start of chemotherapy cycle 3 (each cycle is 21 days; approximately day 43 after the start of chemotherapy) to first event or last follow-up, assessed up to approximately 13 years (follow-up through 31 December 2026)
Overall survival
Time from diagnosis to death from any cause, overall and according to AFP decline kinetics, adjusted for MaGIC risk group.
Time frame: Follow-up up to 31 December 2026 (up to approximately 13 years from diagnosis)
Cumulative incidence of relapse or progression
Cumulative incidence of relapse or progression according to AFP decline kinetics, with death without relapse treated as a competing event (Aalen-Johansen estimator; Fine-Gray models in sensitivity analysis).
Time frame: Follow-up up to 31 December 2026 (up to approximately 13 years from diagnosis)
Prognostic value of AFP level at diagnosis
Association of AFP at diagnosis (log10 AFP and multiples of the age-specific median) with event-free survival, beyond MaGIC risk group.
Time frame: At diagnosis (exposure); outcome assessed through end of follow-up, up to 31 December 2026
Incremental discrimination of AFP kinetics over the MaGIC model
Change in Harrell concordance index (C-index) and time-dependent area under the receiver operating characteristic (ROC) curve at 3 years when AFP kinetic parameters are added to a MaGIC-only model, with bootstrap optimism correction and calibration assessment.
Time frame: 3 years after the start of chemotherapy cycle 3 (each cycle is 21 days)
Prognostic value of beta-human chorionic gonadotropin (beta-hCG) decline kinetics
In patients with elevated beta-hCG at diagnosis, association of beta-hCG half-life (satisfactory if 3 days or less) with event-free survival.
Time frame: Follow-up up to 31 December 2026 (up to approximately 13 years from diagnosis)
Postoperative AFP kinetics in patients managed with surgery alone
AFP half-life and time to AFP normalization after definitive surgery in patients managed with surgery alone and active surveillance, and their association with relapse.
Time frame: From definitive surgery to AFP normalization or relapse; follow-up up to 31 December 2026
Mode of relapse detection and AFP at relapse
Proportion of relapses detected by tumor marker rise, imaging or clinical findings, and serum AFP level at relapse.
Time frame: At relapse, through end of follow-up (31 December 2026)
Long-term ototoxicity
Proportion of patients with hearing loss by International Society of Paediatric Oncology (SIOP) Boston ototoxicity grade on the latest pure-tone audiometry, and hearing aid use, by regimen, number of cycles and cumulative platinum dose.
Time frame: 12 months or more after the end of first-line treatment
Long-term nephrotoxicity
Proportion of patients with estimated glomerular filtration rate (eGFR) below 90 mL/min/1.73 m2 (bedside Schwartz equation) and persistent hypomagnesemia requiring supplementation, by treatment intensity.
Time frame: 12 months or more after the end of first-line treatment
Other long-term toxicities and surgical sequelae
Peripheral neuropathy and bleomycin-related pulmonary toxicity graded by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0; neurogenic bladder, bowel dysfunction and lower-extremity motor deficit.
Time frame: 12 months or more after the end of first-line treatment
Relapse rate and toxicity in a candidate treatment-reduction subgroup (exploratory)
Pre-specified before outcome analysis: patients with MaGIC low- or standard-risk disease, satisfactory AFP decline and cisplatin-based chemotherapy. Relapse rate will be estimated and long-term toxicity modeled as a function of number of cycles and cumulative platinum dose. Descriptive and hypothesis-generating only.
Time frame: Follow-up up to 31 December 2026 (up to approximately 13 years from diagnosis)
Plan to share: No — Under the approved ethics protocol and the Turkish Personal Data Protection Law (KVKK, Law No. 6698), pseudonymized data will be used only for this study, stored on the coordinating center's institutional server in Turkey, and will not be shared outside the study team. Data will be deleted or irreversibly anonymized after study completion.
Start is estimated for Dec 2026; primary completion for May 2027, 5 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neoplasms, Germ Cell and Embryonal →
Ankara City Hospital Bilkent →